00:02 , Jun 19, 2019 |  BC Extra  |  Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

CTTQ, Akeso form JV to develop PD-1 mAb  The Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) subsidiary of Sino Biopharmaceutical Ltd. (HKEX:1177) formed a 50/50 joint venture with Akeso Biopharma Inc. (Zhongshan, China) to...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
19:37 , Apr 20, 2018 |  Completed Offerings  |  Completed Offerings

Tmunity adds $35M to series A round

T cell immunotherapy company Tmunity Therapeutics Inc. (Philadelphia, Pa.) raised an additional $35 million for its series A round from Kleiner Perkins and affiliates, bringing the round's total to $135 million. In January, the company...
11:08 , Apr 19, 2018 |  BC Extra  |  Financial News

Tmunity tops off series A round

T cell immunotherapy company Tmunity Therapeutics Inc. (Philadelphia, Pa.) raised an additional $35 million for its series A round from Kleiner Perkins and affiliates, bringing the round's total to $135 million. In January, the company...
13:43 , Apr 13, 2018 |  BC Week In Review  |  Financial News

Magenta Therapeutics raises $52M series C

Stem cell therapy company Magenta Therapeutics Inc. (Cambridge, Mass.) raised $52 million on April 9 in an untranched, oversubscribed series C round led by Casdin Capital. New investors EcoR1 Capital, Eventide and Watermill were joined...
23:20 , Apr 9, 2018 |  BC Extra  |  Financial News

Magenta Therapeutics raises $52M series C

Magenta Therapeutics Inc. (Cambridge, Mass.) raised $52 million in an untranched, oversubscribed series C round led by Casdin Capital. New investors EcoR1 Capital, Eventide and Watermill were joined by existing investors Be the Match BioTherapies...
23:24 , Jan 26, 2018 |  BioCentury  |  Finance

Tmunity’s A team

An all-star team with a proven track record in cell therapy enabled Tmunity Therapeutics Inc. to raise a $100 million series A round that included opportunistic investments from non-profits Be the Match BioTherapies and Parker...
17:09 , Jan 26, 2018 |  BC Week In Review  |  Financial News

Tmunity raises $100M series A

T cell immunotherapy company Tmunity Therapeutics Inc. (Philadelphia, Pa.) raised $100 million in a series A round Tuesday from new investors Ping An Ventures, Parker Institute for Cancer Immunotherapy, Gilead Sciences Inc. (NASDAQ:GILD) and Be...
00:31 , Jan 24, 2018 |  BC Extra  |  Financial News

Tmunity raises $100M series A

T cell immunotherapy company Tmunity Therapeutics Inc. (Philadelphia, Pa.) raised $100 million in a series A round Tuesday from new investors Ping An Ventures, Parker Institute for Cancer Immunotherapy, Gilead Sciences Inc. (NASDAQ:GILD) and Be...
21:52 , May 5, 2017 |  BioCentury  |  Finance

Magenta’s match

Be the Match BioTherapies’ first ever equity investment was motivated by desire to back a company that shared its goal of helping transplant patients achieve better outcomes, rather than by a planned strategic shift toward...